Bioxodes is a dynamic biotech start-up specialized in the development of novel therapeutics using molecules derived from nature to prevent thrombosis and inflammatory processes


NEWSBioxodes obtains authorization to launch phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers.

Bioxodes has just published very encouraging preclinical activity and safety data of its lead product, Ir-CPI, in the renowed Journal of the American College of Cardiology.

E. Godfroid, CEO and L. Camusot, business developer will represent Bioxodes at BIO-Europe Fall 2019.